EUVIMEDEUVIMED entdecken
Open Access

Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia

Maria Sirenko, Soobeom Lee, Zhengxi Sun, Ronan Chaligne, Sanam Loghavi, Georgios Asimomitis, Charlotte K Brierley, Elsa Bernard, Sheng F Cai, Robert M Myers, Bettina Nadorp, Junya Sango und 23 weitere

Cell Stem Cell · 2025-07 · 32 (7) · 1102-1121.e5

DOI: 10.1016/j.stem.2025.04.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Stem Cell, 2025-07. Verfasst von Maria Sirenko und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA; Laura and Isaac Perlmutter Cancer Center, New York Unive…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Isocitrate Dehydrogenase, Mutation. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Isocitrate dehydrogenase 1/2 (IDH) mutations are early initiating events in acute myeloid leukemia (AML). The complex clonal architecture and cellular heterogeneity in IDH-mutant AML underlies the heterogeneous clinical presentation and outcomes. Integrating single-cell genotyping and transcriptomics, we demonstrate a stem-like and inflammatory phenotype of IDH-mutant AML and identify clone-specific programs associated with NPM1, NRAS, and SRSF2 co-mutations. Furthermore, these clones had distinct responses to treatment with combination IDH inhibitors and chemotherapy, including elimination, reconstitution of myeloid differentiation, or retention within progenitor populations. At relapse after IDH inhibitor monotherapy, we identify upregulated stemness, inflammation, mitochondrial metabolism, and anti-apoptotic factors, as well as downregulated major histocompatibility complex (MHC) class II antigen presentation. At the pre-leukemic stage, we observe upregulation of IDH2-associated pathways, including inflammation. We deliver a detailed phenotyping of IDH-mutant AML and a framework for dissecting contributions of recurrently mutated genes in AML at diagnosis and following therapy, with implications for precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteIsocitrate DehydrogenaseMutationHumansNucleophosminClone CellsAnimals

Stichwörter der Autor:innen

IDH inhibitorsIDH1/2 mutationsacute myeloid leukemiacellular hierarchyclonal architectureclonal evolutionrelapsesingle-cell transcriptomicstargeted therapytreatment resistance

Substanzen

Isocitrate DehydrogenaseNucleophosminNPM1 protein, humanIDH2 protein, humanIDH1 protein, human

Autor:innen und Institutionen

  • Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA; Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY, USA; Louis V. Gerstne…
  • Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA; Department of Biology, New York University, New York, NY, USA.
  • Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA; Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY, USA.
  • Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Biomedical Systems Laboratory, Department of Mechanical Engineering, National Tech…

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • NIGMS NIH HHS
  • NLM NIH HHS
  • NIDDK NIH HHS
  • Mark Foundation For Cancer Research
  • National Heart, Lung, and Blood Institute
  • American Cancer Society

Zitieren

APA

Sirenko, M., Lee, S., Sun, Z., Chaligne, R., Loghavi, S., Asimomitis, G., Brierley, C. K., Bernard, E., Cai, S. F., Myers, R. M., Nadorp, B., Sango, J., Lallo, M., Levine, M. F., Domenico, D., Arango Ossa, J. E., Medina-Martinez, J. S., Menghrajani, K., Lasry, A., …, & Papaemmanuil, E. (2025). Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia. Cell Stem Cell, 32(7), 1102-1121.e5. https://doi.org/10.1016/j.stem.2025.04.012

Vancouver

Sirenko M, Lee S, Sun Z, Chaligne R, Loghavi S, Asimomitis G, et al. Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia. Cell Stem Cell. 2025;32(7):1102-1121.e5. doi:10.1016/j.stem.2025.04.012

BibTeX
@article{Sirenko2025,
  author = {Sirenko, Maria and Lee, Soobeom and Sun, Zhengxi and Chaligne, Ronan and Loghavi, Sanam and Asimomitis, Georgios and Brierley, Charlotte K and Bernard, Elsa and Cai, Sheng F and Myers, Robert M and Nadorp, Bettina and Sango, Junya and Lallo, Morgan and Levine, Max F and Domenico, Dylan and Arango Ossa, Juan E and Medina-Martinez, Juan S and Menghrajani, Kamal and Lasry, Audrey and Mims, Alice S and Desai, Helee and Laganson, Andrea and Famulare, Chris and Patel, Minal and Lozanski, Gerard and Bolton, Kelly L and Viny, Aaron D and Roshal, Mikhail and Levine, Ross L and Papapetrou, Eirini P and Stein, Eytan M and Landau, Dan A and Eisfeld, Ann-Kathrin and Aifantis, Iannis and Papaemmanuil, Elli},
  title = {Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia},
  journal = {Cell Stem Cell},
  year = {2025},
  volume = {32},
  number = {7},
  pages = {1102--1121.e5},
  doi = {10.1016/j.stem.2025.04.012}
}
Kostenlos starten →